$ARTL
ARTELO BIOSCIENCES, INC.

2021 Q1 Form 10-Q Financial Statement

#000164033421000874 Filed on April 13, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q3 2020 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.200M $760.0K $660.0K
YoY Change 81.82% 5.56% 144.44%
% of Gross Profit
Research & Development $307.0K $270.0K $721.3K
YoY Change -57.44% 17.39% 47.21%
% of Gross Profit
Depreciation & Amortization $62.00 $0.00 $124.00
YoY Change -50.0%
% of Gross Profit
Operating Expenses $1.696M $1.030M $1.371M
YoY Change 23.75% 8.42% 80.33%
Operating Profit -$1.696M -$1.371M
YoY Change 23.75%
Interest Expense $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
% of Operating Profit
Other Income/Expense, Net $1.000K $0.00 $408.00
YoY Change 145.1%
Pretax Income -$1.870M -$1.030M -$1.370M
YoY Change 36.5% 21.18% 226.19%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.695M -$1.030M -$1.370M
YoY Change 23.71% 21.18% 222.54%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$110.1K -$224.9K -$399.4K
COMMON SHARES
Basic Shares Outstanding 4.496M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q3 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.22M $2.142M $1.980M
YoY Change 466.67% -51.54% 330.43%
Cash & Equivalents $8.013M $2.142M $1.983M
Short-Term Investments $510.0K $0.00
Other Short-Term Assets $190.0K $200.0K $100.0K
YoY Change 90.0% 1900.0% 400.0%
Inventory
Prepaid Expenses $186.7K $195.0K
Receivables
Other Receivables
Total Short-Term Assets $11.41M $2.337M $2.110M
YoY Change 440.53% -47.4% 339.58%
LONG-TERM ASSETS
Property, Plant & Equipment $124.00 $246.00 $0.00
YoY Change -65.88%
Goodwill
YoY Change
Intangibles $2.039M $2.039M
YoY Change -0.02%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $2.040M $2.039M $2.040M
YoY Change -0.02% -0.06%
TOTAL ASSETS
Total Short-Term Assets $11.41M $2.337M $2.110M
Total Long-Term Assets $2.040M $2.039M $2.040M
Total Assets $13.44M $4.376M $4.150M
YoY Change 223.97% -32.5% 764.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $580.0K $490.0K $430.0K
YoY Change 34.88% -23.37% -27.12%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $589.0K $501.0K $440.0K
YoY Change 33.86% -50.96% -62.71%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $589.0K $501.0K $440.0K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $590.0K $501.0K $440.0K
YoY Change 34.09% -50.88% -62.71%
SHAREHOLDERS EQUITY
Retained Earnings -$12.77M -$9.466M
YoY Change 96.77%
Common Stock $22.21K $5.000K
YoY Change 49.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $13.29M $3.875M $3.708M
YoY Change
Total Liabilities & Shareholders Equity $13.44M $4.376M $4.150M
YoY Change 223.97% -32.5% 764.58%

Cashflow Statement

Concept 2021 Q1 2020 Q3 2020 Q1
OPERATING ACTIVITIES
Net Income -$1.695M -$1.030M -$1.370M
YoY Change 23.71% 21.18% 222.54%
Depreciation, Depletion And Amortization $62.00 $0.00 $124.00
YoY Change -50.0%
Cash From Operating Activities -$1.742M -$880.0K -$1.400M
YoY Change 24.43% -16.98% 89.19%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$510.0K
YoY Change
Cash From Investing Activities -$2.044M $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $6.009M 1.710M 0.000
YoY Change -74.48% -100.0%
NET CHANGE
Cash From Operating Activities -$1.742M -880.0K -1.400M
Cash From Investing Activities -$2.044M 0.000 0.000
Cash From Financing Activities $6.009M 1.710M 0.000
Net Change In Cash $2.230M 830.0K -1.400M
YoY Change -259.29% -79.95% -500.0%
FREE CASH FLOW
Cash From Operating Activities -$1.742M -$880.0K -$1.400M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$1.742M -$880.0K -$1.400M
YoY Change 24.43% -300.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
246 USD
CY2021Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2039417 USD
CY2020Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2039417 USD
CY2021Q1 us-gaap Assets
Assets
13444737 USD
CY2020Q3 us-gaap Assets
Assets
4376862 USD
CY2021Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
583966 USD
CY2020Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
490218 USD
CY2021Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
5000 USD
CY2020Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
11959 USD
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
588966 USD
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
6250000 shares
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
502177 USD
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
6250000 shares
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
186735 USD
CY2020Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
195127 USD
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10706431 USD
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2142072 USD
CY2021Q1 us-gaap Assets Current
AssetsCurrent
11405196 USD
CY2020Q3 us-gaap Assets Current
AssetsCurrent
2337199 USD
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1502 USD
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1363 USD
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
124 USD
CY2021Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
512030 USD
CY2020Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
0 USD
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
12855771 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
3874685 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
9053726 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
5461213 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
4963364 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
3708054 USD
CY2021Q1 us-gaap Depreciation
Depreciation
62 USD
CY2020Q1 us-gaap Depreciation
Depreciation
124 USD
CY2020Q1 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
0 USD
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
0 USD
CY2020Q1 artl Change In Fair Value For Period Of Warrant Derivative Liability
ChangeInFairValueForPeriodOfWarrantDerivativeLiability
0 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2155 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
30495 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-1865921 USD
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-1434645 USD
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-1306361 USD
CY2020Q4 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-16235 USD
CY2019Q4 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
16344 USD
CY2020Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6578553 USD
CY2020Q4 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
10500 USD
CY2021Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
10500 USD
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1982547 USD
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4423965 USD
us-gaap Net Income Loss
NetIncomeLoss
-3300566 USD
us-gaap Professional Fees
ProfessionalFees
481609 USD
us-gaap Net Income Loss
NetIncomeLoss
-2676487 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
25763 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-15862 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3316428 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-2706982 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2650724 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.79
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
836881 USD
us-gaap Professional Fees
ProfessionalFees
642251 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-15862 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1272336 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1388244 USD
us-gaap Depreciation
Depreciation
122 USD
us-gaap Depreciation
Depreciation
248 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
25763 USD
us-gaap Operating Expenses
OperatingExpenses
3302721 USD
us-gaap Operating Expenses
OperatingExpenses
2706982 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
us-gaap Operating Income Loss
OperatingIncomeLoss
-3302721 USD
artl Change In Fair Value For Period Of Warrant Derivative Liability
ChangeInFairValueForPeriodOfWarrantDerivativeLiability
29501 USD
us-gaap Share Based Compensation
ShareBasedCompensation
273416 USD
us-gaap Interest Paid Net
InterestPaidNet
0 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
109841 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
79420 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2454114 USD
CY2020Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6578553 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
15151 USD
artl Refund For Fractional Stock
RefundForFractionalStock
-117 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-11888 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-3601 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
25760 USD
us-gaap Interest Paid Net
InterestPaidNet
0 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
us-gaap Share Based Compensation
ShareBasedCompensation
392817 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-10446 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
88051 USD
artl Common Shares Issued For Settlement Of Stock Payable
CommonSharesIssuedForSettlementOfStockPayable
100000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2819096 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1011447 USD
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
-8338 USD
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
-3040 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11897751 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8564359 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2441418 USD
artl Common Shares Issued For Deposit Of Exercise Of License
CommonSharesIssuedForDepositOfExerciseOfLicense
539417 USD
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000 shares
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000 shares
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22213112 shares
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4991587 shares
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22213112 shares
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4991587 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10120000 shares
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
22213 USD
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
4992 USD
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
25551842 USD
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
13271549 USD
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-12766184 USD
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9465618 USD
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
47900 USD
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
63762 USD
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13444737 USD
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4376862 USD
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1006489 USD
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
433722 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1388012 USD
CY2021Q1 us-gaap Professional Fees
ProfessionalFees
197599 USD
CY2020Q1 us-gaap Professional Fees
ProfessionalFees
215382 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
663359 USD
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
721306 USD
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
1867509 USD
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
1370534 USD
CY2021Q1 artl Common Stock Par Value Before Amendment
CommonStockParValueBeforeAmendment
0.001
CY2021Q1 artl Common Stock Shares Authorized Before Amendment
CommonStockSharesAuthorizedBeforeAmendment
18750000 shares
CY2020Q4 artl Number Of Common Stock Purchased By Warrants Which Sold Pursuant To Exercise Of Overallotment Option
NumberOfCommonStockPurchasedByWarrantsWhichSoldPursuantToExerciseOfOverallotmentOption
1320000 shares
CY2020Q4 artl Common Stock Sold Pursuant To Exercise Of Overallotment Option
CommonStockSoldPursuantToExerciseOfOverallotmentOption
1320000 shares
CY2020Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
10120000 shares
artl Warrant Weighted Average Life Granted
WarrantWeightedAverageLifeGranted
P5Y
CY2021Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
253 USD
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
1335 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1867509 USD
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1370534 USD
CY2020Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
408 USD
us-gaap Interest And Other Income
InterestAndOtherIncome
820 USD
us-gaap Interest And Other Income
InterestAndOtherIncome
994 USD
CY2021Q1 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
1335 USD
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1588 USD
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
408 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-1370126 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
373 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
9419 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
373 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
9419 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1865548 USD
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1360707 USD
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.40
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16986990 shares
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3425928 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13573636 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3393764 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y9M7D
artl Share Based Payment Stock Option Granted Weighted Average Remaining Life
ShareBasedPaymentStockOptionGrantedWeightedAverageRemainingLife
P10Y
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
237237 shares
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.48
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y9M
artl Net Change In Fair Value Of Marketable Securities
NetChangeInFairValueOfMarketableSecurities
-1335 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1176 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1176 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7590000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
5326144 USD
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
1392 USD
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
6420 USD
artl Cancellation Of Common Shares
CancellationOfCommonShares
6 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
510695 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
-0 USD
us-gaap Reclassifications
Reclassifications
<div> <p style="MARGIN:0px 0px 0px 0in;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><em>Reclassifications</em></strong></span></span></p> <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Certain prior year amounts have been reclassified to conform with the current year presentation.</span></span></p> </div>
CY2019Q4 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
13000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
10500 USD
CY2020Q4 us-gaap Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation
40868 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation
330949 USD
CY2019Q4 us-gaap Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation
155019 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation
97397 USD
CY2021Q1 artl Common Shares Value Issued For Exercise Of Warrant
CommonSharesValueIssuedForExerciseOfWarrant
5326144 USD
CY2019Q4 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
15151 USD
CY2019Q4 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
539417 USD
CY2019Q4 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
100000 USD
CY2019Q4 artl Adjustments To Additional Paid In Capital Refund For Fractional Stock
AdjustmentsToAdditionalPaidInCapitalRefundForFractionalStock
-117 USD
CY2020Q1 us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
-2500 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-510695 USD
artl Additional Issuance Of Series D Shares Per The Terms Of The Subscription Agreements
AdditionalIssuanceOfSeriesDSharesPerTheTermsOfTheSubscriptionAgreements
7 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7715246 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2616771 shares
CY2021Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 USD
us-gaap Federal Deposit Insurance Corporation Premium Expense
FederalDepositInsuranceCorporationPremiumExpense
10000000 USD
artl Number Of Warrant Exercised
NumberOfWarrantExercised
7101525 shares
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21000 USD
CY2021Q1 artl Unamortized Value Of Stock Based Compensation
UnamortizedValueOfStockBasedCompensation
12833 USD
artl Warrant Weighted Average Life Exercised
WarrantWeightedAverageLifeExercised
P4Y8M8D
CY2021Q1 artl Warrant Intrinsic Value
WarrantIntrinsicValue
3290138 USD
CY2021Q1 artl Marketable Securities Adjusted Cost
MarketableSecuritiesAdjustedCost
514170 USD
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
2140 USD

Files In Submission

Name View Source Status
0001640334-21-000874-index-headers.html Edgar Link pending
0001640334-21-000874-index.html Edgar Link pending
0001640334-21-000874.txt Edgar Link pending
0001640334-21-000874-xbrl.zip Edgar Link pending
artl-20210228.xml Edgar Link completed
artl-20210228.xsd Edgar Link pending
artl-20210228_cal.xml Edgar Link unprocessable
artl-20210228_def.xml Edgar Link unprocessable
artl-20210228_lab.xml Edgar Link unprocessable
artl-20210228_pre.xml Edgar Link unprocessable
artl_10q.htm Edgar Link pending
artl_ex311.htm Edgar Link pending
artl_ex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending